Five gentamicin assay procedures (a bioassay, an enzyme immunoassay, a latex agglutination inhibition test, a fluorescence immunoassay, and a radioimmunoassay) were evaluated to determine which was optimal for our laboratory. The evaluation was based on recovery and precision studies and results of analyses of patient samples, as well as technical assay performance factors. The latex agglutination inhibition test appears useful for laboratories performing only occasional assays for gentamicin; however, the fact that some rheumatoid factor-positive sera, as well as some other sera for unknown reasons, may give falsely low values is a potential drawback to this procedure. Because of its accuracy, precision, rapid turn-around time, and relative simplicity of performance, we selected the enzyme immunoassay procedure for routine use for gentamicin assays in our laboratory. separate human sera to give final concentrations of 0, 1, 2, 4, 8, 12, and 16 dg/ml. Four categories of sera were selected from patients not receiving gentamicin: normal to visual inspection (nine patients); lipemic (three patients); icteric (three patients); hemolyzed (three patients). Portions (250 ,l) of each serum at each concentration were stored at -70°C until just before assay. These studies were not performed using the bioassay or RIA methods. For statistical handling of the data, when an assay gave a result of "less than" some lower limit on a sample to which no gentamicin had been added, a concentration of 0 Mg/ml was assigned to that sample for that determination. If any gentamicin had been added and a result less than some lower limit was obtained, a concentration of 0.5 kg/ml was assigned to that sample for that determination. If a result of "greater than" some upper limit was obtained on one or both of duplicate determinations, neither of the values was used in the statistical analysis of the data.
Five gentamicin assay procedures (a bioassay, an enzyme immunoassay, a latex agglutination inhibition test, a fluorescence immunoassay, and a radioimmunoassay) were evaluated to determine which was optimal for our laboratory. The evaluation was based on recovery and precision studies and results of analyses of patient samples, as well as technical assay performance factors. The latex agglutination inhibition test appears useful for laboratories performing only occasional assays for gentamicin; however, the fact that some rheumatoid factor-positive sera, as well as some other sera for unknown reasons, may give falsely low values is a potential drawback to this procedure. Because of its accuracy, precision, rapid turn-around time, and relative simplicity of performance, we selected the enzyme immunoassay procedure for routine use for gentamicin assays in our laboratory.
Gentamicin continues to be a widely used antimicrobial agent for the treatment of a variety of serious infections. It is important to be able to determine quickly and accurately the concentration of gentamicin in serum, and occasionally in other both fluids, because of its low therapeutic index. A variety of techniques is available for gentamicin measurement. It was the purpose of this study to evaluate five different techniques, a bioassay, an enzyme immunoassay (EMIT), a latex agglutination inhibition (card) test, a fluorescence immunoassay (FIA), and a radioimmunoassay (RIA), to determine which was optimal for our laboratory.
MATERIALS AND METHODS
Recovery studies. Gentamicin sulfate (Schering Corp., Kenilworth, N.J.) concentrated solution was prepared by drying powdered gentamicin sulfate for 3 h at 60°C under partial vacuum and then weighing and dissolving the gentamicin in 0.1 M potassium phosphate buffer (pH 8.0) to a final concentration of 1,000 Mg/ml. This solution was then diluted in 18 separate human sera to give final concentrations of 0, 1, 2, 4, 8, 12, and 16 dg/ml. Four categories of sera were selected from patients not receiving gentamicin: normal to visual inspection (nine patients); lipemic (three patients); icteric (three patients); hemolyzed (three patients). Portions (250 ,l) of each serum at each concentration were stored at -70°C until just before assay. These studies were not performed using the bioassay or RIA methods. For statistical handling of the data, when an assay gave a result of "less than" some lower limit on a sample to which no gentamicin had been added, a concentration of 0 Mg/ml was assigned to that sample for that determination. If any gentamicin had been added and a result less than some lower limit was obtained, a concentration of 0.5 kg/ml was assigned to that sample for that determination. If a result of "greater than" some upper limit was obtained on one or both of duplicate determinations, neither of the values was used in the statistical analysis of the data.
Precision studies. Concentrated gentamicin sulfate solution (described above) was added to pooled human serum from Clinical Center patients to give final concentrations of 3, 6, and 12 ig of gentamicin per ml. Portions of 250 fl and 5 ml of serum at each concentration were stored at -70°C until just before assay. To determine intrarun precision, 30 assays at each concentration were performed on the same day. Precision studies were not performed by the bioassay procedure.
Patient samples. A total of 110 serum samples were selected from Clinical Center patients who were being treated with gentamicin and other antimicrobial agents. Samples were selected after assay by our routine bioassay procedure to include a range of gentamicin concentrations from < 1 to 10.5 fig/ml. After completion of the bioassay, the residual serum was kept frozen at -20°C in screw-capped glass vials for up to 7 months before being thawed and divided into 250-dl portions, which were refrozen and stored at -70°C. These were thawed just before assay by one of the non-bioassay procedures. For statistical handling of the data, when an assay gave a result less than some lower limit (generally 1 tig/ml), a gentamicin concentration of 0.5 lig/ml was assigned to that specimen. If a result greater than some upper limit was obtained, that value was not used in the statistical analysis of the data.
Bioassay procedure. Bioassay results were obtained by our routine procedure, performed as previously described (2) Table 3 shows the results of the studies on intra-run precision. the card test because we felt that only very rarely would a clinical laboratory performing gentamicin assays know that a particular sample was positive for rheumatoid factor. Table 5 presents the results of the linear regression analyses of the data in Fig. 1 to 4 . The last column in this table shows the 95% confidence interval for a sample determined to be 6.0 kg/ml by the EMIT procedure, when assayed by the other procedures (1) . The numbers may be approximated by substituting the number 6 for the EMIT value (x value) in the equations of the form y = mx + b and adding the quantity two times the standard error of the estimate. Table 6 shows the reagent cost of measuring a gentamicin serum concentration, either as a single sample or as a single sample analyzed in a batch of six samples, for the EMIT, FIA, and card test. Table 5 for regression statistics. Technical considerations. (i) Bioassay. Advantages of the bioassay include the lack of need for sophisticated and costly instrumentation, relative simplicity of performance, and broad applicability to virtually any antimicrobial agent. The techniques for setting up a bioassay are familiar to most microbiologists. Disadvantages of the bioassay are the time required from specimen receipt to result availability (a minimum of 5 h) and interference by other antibiotics which either cannot be inactivated or for which resistant assay organisms are not available.
(ii) EMIT. Advantages of the EMIT assay are extremely rapid turn-around time (about 2 min per specimen after a standard curve has been established), relative ease of performance, and establishment of a standard curve (usable for at least 24 h) independently of specimen assays. This last feature means that "stat" specimens can easily be handled, and also means that, should there be any problems with the establishment of a standard curve, there has been no loss of time, reagents, or samples from specimen processing. We also found the quality control features of the EMIT to be especially useful. Specifically, precise intervals are given within which certain calibrator points should fall, and precise limits for acceptability of the results of the gentamicin control are stated. Only 100 pl of serum is required for a duplicate determination. According to the package insert there is no known interference with the assay by antibiotics other than sisomicin or netilmicin. A disadvantage of the procedure is that occasionally there was some problem establishing an acceptable standard curve; this difficulty was usually related to the 16-,ug/ml calibrator and generally required only re-assaying this calibrator one to three times more to establish a satisfactory value. It was our impression that, after most of the reagents in a given bottle (designated "A" or "B" by the manufacturer) had been used up, it was occasionally difficult to establish a standard curve with these small volumes. This problem may have been due to difficulties with accurate aspiration when only small volumes of reagent remained in the bottles; we have since found that the problem disappears when such smail volumes (with material of the same lot number) are pooled.
(iii) Card test. Advantages of this procedure include its lack of dependence on complex equipment, lack of need for a standard curve, and rapidity. According to information received from the manufacturer, sisomicin does cross-react with the assay; it is not known whether netilmicin also cross-reacts with the assay. According to the package insert there are no other known cross-reacting antibiotics. Disadvantages we found were as follows. Since there is no "batching" with this technique, the time involved for running large numbers of specimens becomes considerable. Also, as noted by the manufacturer, an elevated rheumatoid factor may cause a falsely low assay result. We found this to be a problem up to a gentamicin concentration of 4 ,ug/mI in one patient sample, in which the level was <1.0 ,g/mI by latex agglutination inhibition but at least 4.0 ,ug/ml by all the other procedures.
In addition, as noted above, two other patient samples gave inexplicably low results by this procedure. In the recovery studies, in two sera that were visually normal, an unusual type of agglutination occurred in the lower dilutions of all gentamicin concentrations. This agglutination was presumed to be due to an interfering substance, since it disappeared at higher serum dilutions. The presence of this phenomenon meant that in these two sera only the higher concentrations of gentamicin could be accurately determined. For these two sera, gentamicin concentrations up to and including 4,g/ml were all read as less than the lowest concentration measurable by each of the two cards used at each concentration. Therefore, for the samples to which 0, 1, 2, and 4 ,ug of gentamicin had been added per ml, values of 0, 0.5, 0.5, and 0.5 ,ug/ml, respectively, were assigned. Finally, there is sometimes difficulty in determining the precise agglutination inhibition endpoint; this difficulty decreases but does not disappear with familiarity with the procedure. The bioassay procedure appears less accurate than either RIA or EMIT and also has an excessively long turn-around time.
The EMIT procedure has previously been compared with a bioassay (3) and an RIA (4) and was found to perform well in those studies. Because of its accuracy, precision, rapid turnaround time, and relative simplicity of performance as determined in our study, we selected the EMIT procedure for routine use for gentamicin assays in our laboratory. Since the conclusion of this study, Syva has developed a computer program for use with the assay; this program eliminates the need for manual plotting of a standard curve and makes performance of the assay procedure still more simple. We should note that our laboratory has established the policy of diluting any specimen and reassaying the dilution if the initial determination is -10 ig/ml.
Only small numbers of severely hemolyzed, icteric, and lipemic sera were tested, and all of these were sera to which gentamicin had been added in the laboratory. No patient sera that were severely hemolyzed, icteric, or lipemic were tested. Therefore, despite the fact that we detected no problem with assaying hemolyzed sera, and no problem assaying icteric sera with the EMIT procedure, we are not prepared to state that one can accurately assay severely hemolyzed or icteric sera by either the FIA or EMIT procedure. We do believe, however, that our data demonstrate that lipemic sera cannot be adequately assayed by the EMIT procedure. With all of the procedures, it is imperative that the manufacturer's instructions be followed precisely.
There is considerable variation among the methods both in the cost of reagents alone and in technologist time, as noted in Tables 6 and 7 . Actual reagent costs per test may differ greatly from these theoretical costs if standard curves or entire runs have to be repeated, as noted above. As 
